Shares of Merck & Company, the pharmaceutical giant, fell for a second day amid analysts' predictions of a price war in the lucrative market for cholesterol-lowering drugs. Earlier this week, Sandoz Ltd., a Merck rival, said it would sell its new drug at nearly 50 percent below the prices of existing products, including those of Merck.
